| Literature DB >> 25374433 |
Thomas Skripuletz1, Philipp Schwenkenbecher1, Kaweh Pars1, Matthias Stoll2, Josef Conzen3, Seza Bolat4, Refik Pul1, Ralf-Peter Vonberg5, Ludwig Sedlacek5, Ulrich Wurster1, Martin Stangel1, Corinna Trebst1.
Abstract
Cryptococcal meningoencephalitis represents a serious infection of the central nervous system, where reliable prognostic factors during the disease course are needed. Twenty-one patients diagnosed with cryptococcal meningoencephalitis in a German university hospital from 1999 to 2013 were analysed retrospectively. CSF parameters were analysed prior to therapy and during antifungal treatment and were compared between patients who survived or deceased. Fifteen patients clinically improved after antifungal therapy, while six patients died. No differences were observed between the outcome groups for the CSF parameters cell count, lactate, total protein, and CSF-serum albumin quotients (QAlb). Follow-up examinations of serum cryptococcal antigen titer and CSF cell count have shown that these parameters cannot be used to monitor the efficacy of antifungal therapy as well. In contrast, the course of QAlb during therapy was indicative for the outcome as a possible prognostic marker. In patients with clinical improvement QAlb values were falling under therapy, while rising QAlb values were found in patients with fatal outcome indicating a continuing dysfunction of the blood-CSF barrier. In conclusion, our results indicate that, among the various CSF parameters, the course of QAlb presents a promising marker that might be used to monitor the efficacy of antifungal therapy.Entities:
Mesh:
Year: 2014 PMID: 25374433 PMCID: PMC4211327 DOI: 10.1155/2014/162576
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Patient's characteristics.
| Parameter | All patients ( | Survivors ( | Nonsurvivors ( |
|---|---|---|---|
| Characteristics | |||
| Age, years (mean) | 44 (±16) | 43 (±16) | 46 (±17) |
| Male (no.) | 16 | 11 | 5 |
| Duration of symptoms to diagnosis, days (mean) | 16 (±13) | 16 (±16) | 16 (±6) |
| Symptoms on presentation | |||
| Headache (no.) | 15 | 12 | 3 |
| Disturbance of consciousness (no.) | 13 | 9 | 4 |
| Fever (no.) | 10 | 6 | 4 |
| Nausea and vomiting (no.) | 8 | 8 | 0 |
| Focal neurologic deficits (no.) | 3 | 3a | 0 |
| Stiff neck (no.) | 3 | 2 | 1 |
| Seizures (no.) | 1 | 0 | 1 |
| Complications during hospitalization | |||
| Neurologic complications | |||
| Progressive consciousness disturbance (no.) | 6 | 0 | 6 |
| Seizures (no.) | 3 | 1 | 2 |
| Focal neurologic deficits (no.) | 3 | 1b | 2c |
| Cerebral infarction (no.) | 2 | 0 | 2 |
| Nonneurologic complications | |||
| Electrolyte disturbance (no.) | 21 | 15 | 6 |
| Elevated transaminases (no.) | 17 | 13 | 4 |
| Hypercreatinemia (no.) | 11 | 8 | 3 |
| Allergic reaction (no.) | 2 | 2 | 0 |
aFocal neurologic deficits: aphasia (3/3) and ataxia (1/3).
bFocal neurologic deficit: abducens nerve palsy (1/1).
cFocal neurologic deficit: abducens nerve palsy (2/2) and facial palsy (1/2).
Age and duration of symptoms to diagnosis are presented by mean value and standard deviation.
Characteristics of HIV infected patients.
| All HIV patients ( | Survivors ( | Nonsurvivors ( | |
|---|---|---|---|
| Characteristics in the HIV group | |||
| Previous HIV diagnosis (no.) | 7 | 5 | 2 |
| Previous AIDS-defining illness (no.) | 4 | 3a | 1b |
| On ART while onset of symptoms (no.) | 2 | 1 | 1 |
| Concurrent infections on admission (no.) | 11 | 7c | 4d |
| Laboratory findings on presentation | |||
| Serum HIV viral load (log10 copies/mL) | 5.48 (5.50) | 5.50 (5.50) | 5.40 (5.53) |
| CD4 count (cells/ | 43.38 (60.62) | 41.75 (61.01) | 48.25 (68.44) |
| T4/T8 ratio | 0.08 (0.07) | 0.07 (0.07) | 0.09 (0.09) |
aAIDS-defining illness: pneumocystis jiroveci pneumonia (1/3), progressive multifocal encephalopathy (1/3), and wasting syndrome (1/3).
bAIDS-defining illness: pneumocystis jiroveci pneumonia (1/1).
cConcurrent infections: candidiasis (6/7), cytomegalovirus infection (3/7), cryptosporidiosis (1/7), and hepatitis C (1/7).
dConcurrent infections: candidiasis (4/4) and cytomegalovirus infection (1/4).
Laboratory findings are presented by mean value and standard deviation.
Figure 1Examples of abnormal neuroradiological findings in cryptococcal meningoencephalitis. (a) presents the typical pattern of cryptococcal gelatinous pseudocysts located in lentiform and caudate nuclei (T2WI hyperintense signal) while T1WI sequences ((b), arrow head) show a hypointense signal without enhancement in the T1 C+ image ((c), arrow head). Signs of meningitis are shown by leptomeningeal enhancement in the cerebellar Gyri in axial ((d), arrow heads) and coronal (e) T1 C+ scans. (f) presents signs of basal meningitis demonstrated by leptomeningeal enhancement (arrow head). Hydrocephalus is shown in axial FLAIR sequences in (g) and (h). The enlargement of the frontal and dorsal horns of the lateral ventricles with a hyperintense rim of the periventricular white matter indicates a CSF extravasation. A CCT scan performed 5 days later shows increased ballooning of the third ventricle and a progressive enlargement of the lateral ventricles (i).
Neuroimaging findings.
| Neuroradiological findings | All patients ( | Survivors ( | Nonsurvivors ( |
|---|---|---|---|
| Pseudocysts (no.) | 6 | 4 | 2 |
| Dilated Virchow-Robin spaces (no.) | 4 | 4 | 0 |
| Parenchymal nodules/cryptococcomas (no.) | 0 | 0 | 0 |
| Radiological meningitis (no.) | 3 | 2 | 1 |
| Basal vasculitis (no.) | 2 | 0 | 2 |
| Cerebral infarction (no.) | 3 | 1 | 2 |
| Hydrocephalus (no.) | 3 | 2 | 1 |
| Hyperintense T2W signals (no.) | 12 | 10 | 2 |
| HIV-encephalopathy (no.) | 1 | 1 | 0 |
| Cerebral atrophy (no.) | 7 | 5 | 2 |
Neuroradiological analysis of magnetic resonance image scans of the brain collected at baseline from twenty-one patients infected with cryptococcal meningoencephalitis.
Cerebrospinal fluid.
| Parameter | All patients ( | Survivors ( | Nonsurvivors ( |
|---|---|---|---|
| Leukocytes CSF (cells/ | 151 (±221) | 158 (±256) | 132 (±103) |
| Lactate CSF (mmol/L) | 3.6 (±1.1) | 3.5 (±0.9) | 4.0 (±1.6) |
| Protein CSF (mg/L) | 1074 (±734) | 1071 (±793) | 1081 (±627) |
| Albumin quotient CSF/serum | 18.7 (±15.0) | 18.9 (±15.1) | 18.3 (±16.3) |
| IgG synthesis CSF (no.) | 4 | 1 | 3 |
| IgA synthesis CSF (no.) | 1 | 0 | 1 |
| IgM synthesis CSF (no.) | 5 | 3 | 2 |
| CSF oligoclonal bands (no.) | 12 | 8 | 4 |
Baseline cerebrospinal fluid (CSF) results from patients infected with cryptococcal meningoencephalitis prior to therapy. Laboratory findings are presented by mean value and standard deviation.
Figure 2Illustration of CSF parameters in cryptococcal meningoencephalitis. In (a) values present CSF cell counts while (b)-(c) show values of total CSF protein and CSF-serum albumin quotient (QAlb) after onset of symptoms and during disease course and antifungal therapy. Initial CSF analysis was performed in all patients, while during follow-up CSF was analysed in thirteen patients (eight patients with good outcome and five patients with fatal outcome). Black points mark values of patients with clinical improvement, while red triangles indicate values of patients with the outcome death. On the right side additional graphs present mean values and standard deviation of both groups in the course of antifungal therapy.